Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.45 |
| ▸ | GNPAT | O15228 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 12/20 | 0.43 |
| ▸ | FNTB | P49356 | 12/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 10/20 | 0.43 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30463248 | 1.00 | FOLH1 (0.46) | FOLH1SIRT5GNPATFNTAFNTB | |
| SCHEMBL30463274 | 1.00 | FOLH1 (0.46) | FOLH1SIRT5GNPATFNTAFNTB | |
| SCHEMBL29660264 | 0.97 | GNPAT (0.45) | FOLH1SIRT5GNPATFNTAFNTB | |
| SCHEMBL30463272 | 0.97 | FNTA (0.45) | FOLH1SIRT5GNPATFNTAFNTB | |
| SCHEMBL31157701 | 0.95 | BACE1 (0.45) | FOLH1SIRT5GNPATFNTAFNTB | |
| SCHEMBL31157745 | 0.95 | FOLH1 (0.45) | FOLH1SIRT5GNPATFNTAFNTB | |
| SCHEMBL30998021 | 0.94 | SIRT5 (0.53) | FOLH1SIRT5GNPATIL23R | |
| SCHEMBL31157760 | 0.94 | SIRT5 (0.53) | FOLH1SIRT5GNPATIL23R | |
| SCHEMBL31157647 | 0.94 | SIRT5 (0.53) | FOLH1SIRT5GNPATIL23R | |
| SCHEMBL12066140 | 0.94 | SIRT5 (0.53) | FOLH1SIRT5GNPATIL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161409-A1 | COMPOSITIONS FOR TREATING HYPERHIDROSIS | PROSPERA BIOTECH, S.L. (ES) | 2025-05-22 | — | — | US | disclosed |
| EP-3852781-B1 | COMPOSITIONS COMPRISING ACYLATED TETRAPEPTIDES FOR DERMATOLOGICAL AND COSMETIC APPLICATIONS | MILLER NORMAN E (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-113015538-B | Compositions comprising acylated tetrapeptides for dermatological and cosmetic applications | 诺曼·E·米勒 | 2025-01-14 | — | — | CN | disclosed |
| EP-3548510-B1 | COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES | LUBRIZOL ADVANCED MAT INC (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-4362904-A1 | COSMETIC, NON-THERAPEUTIC USES OF PEPTIDES | Lubrizol Advanced Materials, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-110997696-B | Cosmetic composition for improving skin comprising fusion protein to which skin permeation promoting peptide is bound | 株式会社LG生活健康 | 2024-03-05 | — | — | CN | disclosed |
| EP-4247835-A1 | TETRAPEPTIDES, COMPOSITIONS COMPRISING THEM, AND THEIR COSMETIC USE | SEDERMA (FR) | 2023-09-27 | — | — | EP | disclosed |
| US-20230190616-A1 | COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| EP-4188319-A1 | COSMETIC OR DERMATOLOGICAL PEPTIDE-BASED TREATMENT OF THE SKIN AND ITS INTEGUMENTS | SEDERMA (FR) | 2023-06-07 | — | — | EP | disclosed |
| CN-111620928-B | Large-scale synthesis method of hexapeptide | 陕西慧康生物科技有限责任公司 | 2023-02-28 | — | — | CN | disclosed |
| EP-4120998-A1 | COSMETIC COMPOSITION AND TREATMENT FOR TREATING SKIN SAGGING | SEDERMA (FR) | 2023-01-25 | — | — | EP | disclosed |
| WO-2023275811-A1 | COSMETIC, NON-THERAPEUTIC USES OF PEPTIDES | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| EP-4076367-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION ACTING IN PARTICULAR ON THE EFFECTS OF BLUE LIGHT ON SKIN AND ITS APPENDAGES, AND ASSOCIATED USES | SEDERMA (FR) | 2022-10-26 | — | — | EP | disclosed |
| CN-111714395-B | Polypeptide composition compounded by ginkgo biloba extract and application thereof | 南京斯拜科生物科技股份有限公司 | 2022-10-04 | — | — | CN | disclosed |
| EP-4041184-A2 | PEPTIDE BASED COSMETIC OR DERMATOLOGICAL TREATMENT OF THE SKIN AND ITS APPENDAGES | SEDERMA (FR) | 2022-08-17 | — | — | EP | disclosed |
| EP-4037656-A1 | USE OF LEONTODIUM ALPINUM PLANT CELLS FOR AN ANTI-GLYCATION ANTI-AGEING SKIN TREATMENT | SEDERMA (FR) | 2022-08-10 | — | — | EP | disclosed |
| WO-2022106365-A1 | TETRAPEPTIDES, COMPOSITIONS COMPRISING THEM, AND THEIR COSMETIC USE | SEDERMA (FR) | 2022-05-27 | — | — | WO | disclosed |
| CN-114555045-A | Peptide-based cosmetic or dermatological treatment of skin and its appendages | 赛德玛公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-114057838-B | Solid-phase synthesis method of acetyl hexapeptide-8 | 浙江湃肽生物有限公司南京分公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-114057838-A | Solid-phase synthesis method of acetyl hexapeptide-8 | 浙江湃肽生物有限公司南京分公司 | 2022-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190616-A1 | COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES | GLA, ALG3, ANXA6 | FOLH1 3861/4885SIRT5 3611/4885GNPAT 3557/4885 |
| US-20250161409-A1 | COMPOSITIONS FOR TREATING HYPERHIDROSIS | TRPV1, NHERF1, SLC18A1 | FOLH1 3790/4885SIRT5 4118/4885GNPAT 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.